We're delighted to add our latest Educational Series titled: First-line treatment of acute myeloid leukaemia in patients ineligible for standard induction therapy: venetoclax plus azacytidine. This review provides an introduction to AML and current treatments, summarises ESMO Clinical Practice Guidelines and focusses on key data on the use of venetoclax plus azacitidine.
The review includes guiding commentary from Dr Ashish Bajel, a haematologist and BMT physician at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
Please login below to download this issue (PDF)